We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 18.00 | 0.16% | 11,268.00 | 11,222.00 | 11,226.00 | 11,362.00 | 11,220.00 | 11,250.00 | 3,556,178 | 16:35:27 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 29.21 | 173.96B |
From Apr 2019 to Apr 2024
By Oliver Griffin
AstraZeneca PLC (AZN.LN) said Thursday that the U.S. Food and Drug Administration has granted orphan drug designation for Selumetinib, a drug used to treat incurable genetic condition Neurofibromatosis Type 1.
The pharmaceutical company said a U.S. National Cancer Institute-sponsored phase one and two trial is exploring the use of Selumetinib to treat NF1 in pediatric patients. Phase two trial results are expected later in 2018, AstraZeneca said.
The FDA's orphan-drug designation program provides orphan status to medicines that are intended to treat fewer than 200,000 people in the U.S. suffering from rare diseases.
AstraZeneca also said that Selumetinib is being investigated in phase three trials of post-surgery and radiotherapy patients diagnosed with differentiated thyroid cancer.
Write to Oliver Griffin at oliver.griffin@dowjones.com
(END) Dow Jones Newswires
February 15, 2018 02:45 ET (07:45 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
